---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-011706"
form_type: "8-K"
ticker: "ACAD"
cik: "0001070494"
company_name: "ACADIA PHARMACEUTICALS INC"
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:33:16.717517+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Acadia Pharmaceuticals reaffirms 2025 net sales guidance above $1B

## Summary
- Anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance.
- Presented at J.P. Morgan Healthcare Conference on January 13, 2026.
- Corporate slide presentation posted on ir.acadia.com for investor access.

## SEC filing metadata
- accession: 0001193125-26-011706
- form_type: 8-K
- ticker: ACAD
- cik: 0001070494
- company_name: ACADIA PHARMACEUTICALS INC
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1070494/000119312526011706/0001193125-26-011706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1070494/000119312526011706/acad-20260113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-011706
- JSON: https://secwatch.observer/filing/0001193125-26-011706.json
- Plain text: https://secwatch.observer/filing/0001193125-26-011706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.